2024-10-31 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

This report provides a comprehensive analysis of Merck & Co Inc (MRK) stock, covering its performance, technical indicators, recent news, and financial data. 

**1. Performance Analysis:**

Merck & Co Inc (MRK) is a global pharmaceutical company, known for its diverse portfolio of prescription medications, vaccines, and animal health products. 

**Comparison with S&P 500 (VOO):**

* **Cumulative Return (MRK):** 61.17%
* **Cumulative Return (VOO):** 136.74%
* **Divergence:** -75.57%
* **Relative Divergence:** 10.26%

This indicates that MRK has underperformed the S&P 500 by a significant margin. While MRK's cumulative return is positive, it has lagged behind the broader market over the specified period. The relative divergence suggests that MRK's current performance is in the bottom 10% of its historical performance range compared to the S&P 500.

**2. Recent Price Movement:**

* **Last Price:** 103.76
* **5-day Moving Average:** 104.84
* **20-day Moving Average:** 108.29
* **60-day Moving Average:** 113.10

The current price is below all three moving averages, indicating a potential downtrend. The 5-day moving average is closer to the current price, suggesting that the price action might be experiencing some short-term support. However, the larger discrepancies between the current price and the 20-day and 60-day moving averages highlight the longer-term bearish trend.

**3. Technical Indicators:**

* **RSI:** 22.7 - This indicates that MRK is currently in oversold territory.
* **PPO:** -0.37 - This suggests a potential bearish trend in the short term.
* **Delta_Previous_Relative_Divergence:** -20.49 -  This indicates a recent short-term decline in relative divergence.

The technical indicators suggest that MRK is facing downward pressure and might be experiencing a bearish trend. The oversold RSI and negative PPO signal a potential short-term rebound. However, the declining relative divergence suggests that the current price decline is continuing.

**4. Recent Earnings and Forecasts:**

| Date        | EPS    | Revenue        |
|-------------|--------|----------------|
| 2024-08-05  | 2.15   | 16.11 B$       |
| 2024-05-03  | 1.88   | 15.78 B$       |
| 2023-11-03  | 1.87   | 15.96 B$       |
| 2023-08-07  | -2.35  | 15.04 B$       |
| 2024-08-05  | -2.35  | 15.04 B$       |

The most recent earnings report (2024-08-05) showed that MRK exceeded analysts' expectations.  The company posted an EPS of $2.15, surpassing the estimated $1.95. Revenue also exceeded expectations at $16.11 billion, compared to the estimated $15.98 billion. This positive performance demonstrates the company's ability to drive growth and profitability despite industry-wide challenges. 

**5. Financial Data Analysis:**

**1) Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-06-30  | $16.11B    | 76.76%         |
| 2024-03-31  | $15.78B    | 77.56%         |
| 2023-12-31  | $14.63B    | 73.26%         |
| 2023-09-30  | $15.96B    | 73.29%         |
| 2023-06-30  | $15.04B    | 73.24%         |

MRK's revenue has been consistently growing over the past year, demonstrating the strength of its product portfolio. The company's high profit margin indicates its efficient operations and ability to generate strong profits.

**2) Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|-------------|-------------|--------|
| 2024-06-30  | $43.58B    | 12.52% |
| 2024-03-31  | $40.36B    | 11.80% |
| 2023-12-31  | $37.58B    | -3.26% |
| 2023-09-30  | $41.25B    | 11.50% |
| 2023-06-30  | $38.69B    | -15.44% |

The company's equity has been steadily growing, demonstrating a strong financial position. While the ROE has experienced some fluctuation, the recent quarter shows a healthy and positive ROE, indicating effective utilization of shareholder capital.

**6. News and Recent Issues:**

* **Recent Earnings Report:**  MRK's recent earnings report, released on August 5, 2024, was well received by analysts. The company exceeded expectations on both EPS and revenue, demonstrating strong performance and highlighting its resilience in the face of market challenges. 
* **Market Outlook:**  Despite the recent downward price action, several analysts maintain a positive outlook for MRK's long-term performance. The company's strong financial position, robust pipeline of new products, and commitment to innovation continue to drive investor confidence.
* **Analyst Opinions:**  While MRK is currently facing some headwinds, the majority of analysts remain optimistic about the company's future. Many analysts maintain "buy" or "hold" ratings, citing the company's strong fundamentals, proven track record, and potential for future growth.
* **Performance Highlights:**  MRK has consistently demonstrated its ability to develop and bring innovative products to market. Key growth drivers include its blockbuster drug, Keytruda, and its expanding portfolio of vaccines and animal health products.

**7. Overall Analysis:**

MRK is a mature pharmaceutical giant with a robust track record of delivering value to shareholders. The company's recent earnings report suggests a positive outlook for the future, with the continued success of Keytruda and a strong pipeline of new products. Despite the current downtrend, MRK's long-term fundamentals remain strong. Investors looking for a stable, value-oriented investment with the potential for long-term growth might consider adding MRK to their portfolio.

**8.  Recommendations:**

* **Long-Term Investment:** Given MRK's strong fundamentals and potential for growth, a long-term investment approach is recommended. 
* **Potential Entry Point:** The current oversold conditions present a potential entry point for long-term investors.
* **Monitor Keytruda Performance:**  Keep an eye on Keytruda's market performance and potential competition to assess the impact on MRK's future growth.
* **Diversify Portfolio:**  It's important to diversify your portfolio to mitigate risk.

This report provides a starting point for further research and analysis. It is not intended to be a substitute for professional investment advice. Please consult with a qualified financial advisor before making any investment decisions.
